Impact of Race and Genetic Factors on Beta Blocker Effectiveness in Heart Failure. Impact of Race and Genetic Factors on Beta Blocker Effectiveness in Heart Failure

Heart Failure (HF) continues to be an enormous public health problem, despite the many advances in its pharmacotherapy over the past 25 years. The availability of multiple therapeutic options for HF requires individualization of therapy. However, there are currently insufficient tools to guide the optimal selection of therapy. The expansion of human genomic information has led to exciting new opportunities to improve the selection of drug therapy. In order to evaluate whether genetics and other biomarkers impact outcomes and drug response in heart failure, we performed a cohort study of patients with heart failure. Our overall plan was to recruit patients who have heart failure and receive treatment through HAP-HFMG. This allowed us to collect clinical outcomes, and quantify medication adherence via electronic claims data. We collected whole blood samples for genetic and biomarker analysis. The outcomes and adherence data then was tested for association... (for more see dbGaP study page.)